Welcome to the e-CCO Library!

P523: Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naïve Crohn's disease: a subanalysis of DIAMOND trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Motoya S.*1, Nakase H.2, Matsumoto T.3, Watanabe K.4, Hisamatsu T.5, Yoshimura N.6, Ishida T.7, Kato S.8, Nakagawa T.9, Nagahori M.10, Esaki M.11, Matsui T.12, Naito Y.13, Kanai T.14, Suzuki Y.15, Nojima M.16, Watanabe M.10, Hibi T.17 the DIAMOND Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P523: effectiveness of biological treatments for inflammatory bowel disease in the elderly patients
Year: 2022
Source: ECCO'22
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);Miranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez, J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celix, C.(12);Martin-Arranz, M.D.(13);Lopez Sanroman, A.(2);Fernandez-Clotet, A.(3);Merino Murgui, V.(14);Calviño Suarez, C.(5);Florez, P.(6);Lobato Matilla, M.E.(7);Sicilia, B.(8);Soto Escribano, P.(15);Maroto Martin, C.(10);Alonso Abreu, I.(16);Melcarne, L.(17);Elena , P.G.(18);Iyo, E.(19);Elosua Gonzalez, A.(20);Saiz, E.(21);Hernandez Villalba, L.(22);Perez Galindo, P.(23);Torrealba Medina , L.(24);Monsalve Alonso , S.(25);Olmos Jerez, J.A.(26);Dueñas Sadornil , C.(27);Barreiro-De Acosta, M.(5);
Created: Friday, 11 February 2022, 3:56 PM
P523: Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Lim1,2,3, M. Thai2,4, P. Hendy2,4, M. Alchlaihawi5, R. Leong5,6,7, S. Connor6,8, W. Ng6,8, B. Gu6,8, D. van Langenberg9,10, L. Thin11,12, J. Schulberg13,14, M. Kamm13,14, R. Gilmore15, K. Taylor15, O. Sallis16,17, J. Andrews16,17, C. Daker18,19, M. Barclay18,19, G. Wark6,20, S. Ghaly6,20, M. Begun6, K. Krishnaprasad21, J. Begun*2,4,22

Created: Friday, 22 February 2019, 9:41 AM
P523: New guidance on therapeutic drug monitoring; potential clinical and cost implication
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Felwick*, H. Johnson, H. Dewhurst, E. Cadogan, C. Hovell, S. Weaver, S. McLaughlin

Created: Thursday, 21 February 2019, 9:14 AM
P523: Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn's Colitis Care (CCCare): A real world observational study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cheema, M.(1)*;Narouz, I.(2);Pipicella, J.(3);Garden , F.(4);Lynch, K.(5);Andrews, J.(5);Ghaly, S.(2);Connor, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P523: Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe
Year: 2021
Source: ECCO'21 Virtual
Authors: Fiorino, G.(1);Bent-Ennakhil, N.(2);Varriale, P.(3);Braegger, F.(2);Hoefkens, E.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Volmar1, S. Wildt2,3, L.K. Munck2,3

Created: Thursday, 30 January 2020, 10:12 AM
P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluation
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Bruna-Barranco1, P. Alarcon2, A. Lué3,4, C. Gargallo3,4, E. Alfambra4, M. Gimeno5, F. Gomollon2,3,4,6*

Created: Thursday, 21 February 2019, 9:14 AM
P524: Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.
Year: 2022
Source: ECCO'22
Authors: Riviere, P.(1);Kanters, C.(2);Ni, A.(2);Pellet, G.(1);Hupe, M.(1);Aboulhamid, N.(2);Poullenot, F.(1);Bitton, A.(2);Zerbib, F.(1);Lakatos, P.(2);Afif, W.(2);Laharie, D.(1);Bessissow, T.(2);
Created: Friday, 11 February 2022, 3:56 PM
P524: Endoscopic dilations of intestinal stenosis in Crohn's disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Badre, W.(1);Bahlaoui, O.(1);El Rhaoussi, F.Z.(1);Tahiri, M.(1);Haddad, F.(1);Hliwa, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P524: Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adults
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Diederen K.*1, Sahami S.2, Tabbers M.1, Benninga M.1, Kindermann A.1, Tanis P.2, Oomen M.3, Bemelman W.2, de Jong J.3

Created: Wednesday, 20 February 2019, 10:36 AM
P524: Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.(1);Ben-Horin, S.(2);Ye, B.D.(3);Kim, D.H.(4);Reinisch, W.(5)*;
Created: Friday, 14 July 2023, 11:05 AM
P524: Systematic review of calcineurin inhibitors (CNI) and vedolizumab (VDZ) combination therapy in acute severe ulcerative colitis (ASUC)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Lin*1, W-C. Lim1

Created: Friday, 22 February 2019, 9:41 AM
P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Besuyen1, A. Kavanaugh2, R. Westhovens3, K. Winthrop4, S. Lee5, J. Greer6, A. DeZure6, D. An7, L. Ye7, J. Sundy6, L. Meuleners8, R. Alten9, M. Genovese10

Created: Thursday, 30 January 2020, 10:12 AM
P525: A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
Year: 2022
Source: ECCO'22
Authors: Vavricka, S.(1);Zeitz, J.(2);Madanchi, M.(1);Biedermann, L.(1);Morsy, Y.(1);Scharl, M.(1);Gassmann, M.(3);Lutz, T.(3);Kunz, A.(4);Bron, D.(4);Rogler, G.(1);Greuter, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Null1*, H.L. Chang2, T. Lissoos1, M. Luo1, B. Cohen2, B.E. Sands2, A. Atreja2

Created: Thursday, 21 February 2019, 9:14 AM
P525: Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UK
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lenti M.V.*1, Levison S.2, Eliadou E.2, Willert R.2, Kemp K.2, Stansfield C.3, Assadsangabi A.3, Singh S.4, Crooks B.4, Tattersall S.4, Kenneth C.5, Subramanian S.6, Probert C.6, Smith P.7, Liu E.7, Limdi J.K.8, Hamlin P.J.1, Selinger C.P.1

Created: Wednesday, 20 February 2019, 10:36 AM
P525: Patients' Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel
Year: 2021
Source: ECCO'21 Virtual
Authors: Lior, O.(1);Sergeev, I.(1);Ruhimovich, N.(1);Openheim, M.(1);Benjaminov, F.(1);Feldman, D.(1);Ringel, Y.(1);Naftali, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P525: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Taxonera, C.(1)*;Olivares, D.(1);Olga N, L.G.(2);Alba, C.(1);
Created: Friday, 14 July 2023, 11:05 AM
P525: The benefits of anti-TNF drug and antidrug antibody (ADAb) level monitoring in a DGH
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Matthews*1, I. London1, I. Reilly1, T. Maheswaren1, A. Lewis Williams1, S. Michail1

Created: Friday, 22 February 2019, 9:41 AM